Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Hodgkin Disease 50Lymphoma 45Testicular Neoplasms 13Teratoma 12HIV Infections 12Acquired Immunodeficiency Syndrome 11Lymphoma, Large B-Cell, Diffuse 10Lymphoma, Non-Hodgkin 9Head and Neck Neoplasms 8Endodermal Sinus Tumor 8Testicular Germ Cell Tumor 7Sarcoma, Kaposi 7Neoplasms 7Carcinoma, Embryonal 7Seminoma 6Lymphoma, Large-Cell, Immunoblastic 6Lymphoma, Follicular 6Ovarian Neoplasms 5Ovarian Germ Cell Cancer 5Recurrence 4Neoplasms, Germ Cell and Embryonal 4Neoplasm Metastasis 4Carcinoma, Squamous Cell 4Vulvar Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Teratoma, Testicular 2Skin Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Drug-Related Side Effects and Adverse Reactions 2Dendritic Cell Sarcoma, Interdigitating 2

Interventions

Temozolomide 393Radiotherapy 196Bevacizumab 156Radiation 77Magnetic Resonance Spectroscopy 68Lomustine 47Surgical Procedures, Operative 42Carmustine 41pembrolizumab 39Irinotecan 38Nivolumab 32Specimen Handling 27Carboplatin 27Radiosurgery 24Erlotinib Hydrochloride 24Chemotherapy, Adjuvant 23Radiotherapy, Intensity-Modulated 22Drug Therapy 21Cyclophosphamide 20Aminolevulinic Acid 20O(6)-benzylguanine 17sargramostim 16Radiotherapy, Conformal 15temsirolimus 14Granulocyte-Macrophage Colony-Stimulating Factor 14Everolimus 14Vorinostat 13Sorafenib 13poly ICLC 12atezolizumab 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Glioblastoma × Bleomycin × Clear all
NCT00006916 2020-10-26

Radiation Therapy Followed by Bleomycin in Treating Adult Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme

Radiation Therapy Oncology Group

Phase 2 Terminated
19 enrolled 4 charts
CNSSarcoma

Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡